Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical company focused on neurodegenerative diseases, has announced a significant advancement in its intellectual property portfolio. The company has secured full patent coverage for both the original and a new crystalline form of buntanetap, its lead compound. This development ensures protection for the drug's composition, mechanism of action, and its use across multiple indications until 2046.

The new crystalline form of buntanetap has demonstrated improved stability, with bioequivalence confirmed in both animal and human studies. These findings were recently presented at the 2025 Alzheimer’s Association International Conference, highlighting the potential of buntanetap to offer more reliable and effective treatment options for patients suffering from neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD).

This patent expansion is a critical milestone for Annovis Bio, as it not only strengthens the company's position in the neurodegenerative disease treatment market but also enhances the commercial viability of buntanetap. With the global prevalence of neurodegenerative diseases on the rise, the demand for innovative and effective treatments is more pressing than ever. The improved stability of the new crystalline form could significantly impact the drug's shelf life and efficacy, making it a valuable asset in the fight against these debilitating conditions.

For more details on Annovis Bio's groundbreaking work and the full press release, visit https://ibn.fm/gtiNb. Additionally, updates and news related to Annovis Bio can be found in the company’s newsroom at https://ibn.fm/ANVS.